| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 10511296 | Journal of Adolescent Health | 2014 | 9 Pages | 
Abstract
												Data from the Carraguard trial provide no evidence that inclusion of 16- to 17-year-olds in the trial had any detrimental effect on trial participants or on the conduct of research. These data provide an argument motivating the inclusion of sexually active adolescents aged 16-17 years into future trials in order to avoid delaying access to an effective product for adolescents at high risk of HIV acquisition. Careful support for adolescent-inclusive protocols (including appropriate counseling) must be incorporated into study design.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Perinatology, Pediatrics and Child Health
												
											Authors
												Katie D. Ph.D., Barbara A. M.P.H., Michelle M.P.H., Marie M.P.H., Marlena Gehret M.S., Stephanie M.P.H., Thesla Ph.D., Khatija FCPath, Mary Jane Malebo Rathlagana, Pamela Nombali Mthembu, Nomampondomise Ngcozela, 
											